SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2025-02-01 (doe.cl)
Santiago Court of Appeals rejected Synthon Chile claim and confirms partial delivery of clinical studies - | Legal News
The ISP ordered to targe any antecedent that says relationship or contains data that account for the formula of the products consulted, and of any personal data of context and sensitive data that they may contain.
Read more
2025-02-01 (doe.cl)
Santiago Court of Appeals rejected Synthon Chile claim and confirms partial delivery of clinical studies - | Legal News
The ISP ordered to targe any antecedent that says relationship or contains data that account for the formula of the products consulted, and of any personal data of context and sensitive data that they may contain.
Read more
2024-10-31 (bizportal.co.il)
The European Commission imposed a fine of half a billion euros on Teva for its conduct in the Copaxone market
According to the findings of the European Commission's investigation, Teva acted on several fronts to prevent competition in the copaxone market, even after the original patent expired
Read more
2012-09-12 (medischcontact.nl)
battle over generic drug against dementia
Pharmaceutical company Synthon is considering legal follow-up steps after losing an appeal case...
Read more
2012-09-12 (medischcontact.nl)
battle over generic drug against dementia
Pharmaceutical company Synthon is considering legal follow-up steps after losing an appeal case...
Read more
(tijd.be)
UCB files lawsuit against Synthon
Brussels (time) - Biopharma company UCB is filing a lawsuit against the Dutch company Synthon. According to UCB, the generic drug manufacturer has violated the patent on the anti-allergy drug Xyzal. This was reported by the Bloomberg news agency.
Read more
(tijd.be)
UCB files lawsuit against Synthon
Brussels (time) - Biopharma company UCB is filing a lawsuit against the Dutch company Synthon. According to UCB, the generic drug manufacturer has violated the patent on the anti-allergy drug Xyzal. This was reported by the Bloomberg news agency.
Read more
(tijd.be)
UCB files lawsuit against Synthon
Brussels (time) - Biopharma company UCB is filing a lawsuit against the Dutch company Synthon. According to UCB, the generic drug manufacturer has violated the patent on the anti-allergy drug Xyzal. This was reported by the Bloomberg news agency.
Read more
(law360.com)
celgene goes after synthons skin cancer drug generic
Synthon Pharmaceuticals Inc. and Alvogen Pine Brook LLC are infringing four of Celgene Corp.'s patents by seeking approval for a generic version of the blockbuster skin cancer medication Pomalyst, the branded drugmaker told a North Carolina federal court Thursday.
Read more
(law360.com)
celgene goes after synthons skin cancer drug generic
Synthon Pharmaceuticals Inc. and Alvogen Pine Brook LLC are infringing four of Celgene Corp.'s patents by seeking approval for a generic version of the blockbuster skin cancer medication Pomalyst, the branded drugmaker told a North Carolina federal court Thursday.
Read more
(law360.com)
celgene goes after synthons skin cancer drug generic
Synthon Pharmaceuticals Inc. and Alvogen Pine Brook LLC are infringing four of Celgene Corp.'s patents by seeking approval for a generic version of the blockbuster skin cancer medication Pomalyst, the branded drugmaker told a North Carolina federal court Thursday.
Read more
(law360.com)
celgene goes after synthons skin cancer drug generic
Synthon Pharmaceuticals Inc. and Alvogen Pine Brook LLC are infringing four of Celgene Corp.'s patents by seeking approval for a generic version of the blockbuster skin cancer medication Pomalyst, the branded drugmaker told a North Carolina federal court Thursday.
Read more